Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa—Barrett’s esophagus—early esophageal adenocarcinoma—advanced esophageal adenocarcinoma sequence
- 1 March 2017
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (3) , 205-209
Abstract
No abstract availableKeywords
Funding Information
- Medical University of Lodz (503/1-002-01/503-01)
This publication has 31 references indexed in Scilit:
- Diagnostic and Management Implications of Basic Science Advances in Barrett’s EsophagusCurrent Treatment Options in Gastroenterology, 2015
- Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal CancersCancers, 2011
- Interobserver Variability in the Diagnosis of Crypt Dysplasia in Barrett EsophagusAmerican Journal of Surgical Pathology, 2011
- Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancerBritish Journal of Cancer, 2010
- Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinomaDiseases of the Esophagus, 2010
- Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinomaDiseases of the Esophagus, 2010
- Biomarkers in Barrett’s esophagus and esophageal adenocarcinoma: Predictors of progression and prognosisWorld Journal of Gastroenterology, 2010
- Molecular Markers and Genetics in Cancer DevelopmentSurgical Oncology Clinics of North America, 2009
- Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?Cancer Research, 2008
- The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma IncidenceJNCI: Journal of the National Cancer Institute, 2005